Drug Trial Radar · NCT07717736
Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 2031
Study completion Jul 2032
Sponsor
- Lead sponsor
- Abeona Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Master Protocol includes 3 studies (Study A, Study B, and Study C) that will evaluate pz-cel and related processes in the post-marketing setting. Study A investigates the efficacy and safety of non-conforming pz-cel in patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB). Study B enables the collection of additional biopsy samples from patients receiving treatment with pz-cel. Study C assesses the efficacy and safety of pz-cel in patient populations not represented in the VIITAL clinical trial (NCT04227106).
Conditions
- Epidermolysis Bullosa (EB)
- Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- Dystrophic Epidermolysis Bullosa (DEB)
Interventions
Non-conforming pz-cel surgical application to RDEB woundsBiological
Non-conforming pz-cel is pz-cel intended for commercial treatment that did not meet commercial release criteria, but had no safety concerns associated with its use.
Additional biopsiesProcedure
Additional biopsy samples from patients who are expected to receive treatment with pz-cel in the post-marketing setting.
Pz-cel surgical application to DEB woundsBiological
This intervention is for patients requiring special access for application of pz-cel.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Study A - Wound Healing ≥50%Time frame: From Baseline at Week 24 (Month 6)
- Study A - Pain Severity Scale (Wong-Baker FACES)Time frame: At Week 24 (Month 6)
- Study C - Wound Healing ≥50%Time frame: From Baseline at Week 24 (Month 6)
- Study C - Pain Severity Scale (Wong-Baker FACES)Time frame: At Week 24 (Month 6)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.